Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Agenus Inc. (AGEN) for alleged misstatements and omissions related to the effectiveness of its botensilimab and balstilimab combination therapy. Investors who suffered losses exceeding $50,000 are encouraged to contact the firm to discuss their legal rights.
Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (ALLR) following a series of events involving the company’s Dovitinib NDA and SEC investigations. Investors who suffered losses exceeding $50,000 between May 17, 2022 and July 19, 2024 are encouraged to contact Faruqi & Faruqi to discuss their legal options.
Faruqi & Faruqi, LLP, a prominent securities law firm, is investigating potential legal claims against Nano Nuclear Energy Inc. (NNE) on behalf of investors who suffered losses exceeding $50,000 between May 8, 2024, and July 18, 2024. The investigation centers around allegations that NNE made misleading statements about its progress and capabilities, potentially impacting investor confidence and leading to stock price decline.
Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against SeaStar Medical Holding Corporation (SeaStar) and reminds investors of the September 6, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the company. The lawsuit alleges that SeaStar made false and misleading statements about its financial controls and regulatory prospects, leading to a restatement of its financial statements and a subsequent drop in its stock price.
